Tracer library / [213Bi]Bi-PSMA-617
Structure of PSMA-617 (unlabelled parent compound, from PubChem)
Unlabelled parent compoundPubChem CID 122706786

[213Bi]Bi-PSMA-617

Also written as PSMA-617; Pluvicto
Radionuclide
Bi-213 t½ 45.6 min
Modality
Therapy
Production route
—
Stage
—
Syntheses indexed
0
Prostate cancerDosimetry and biodistribution studiesPSMA-directed radioligand therapy

What it is

Compound class
PSMA-targeting small molecule (urea-based PSMA ligand)
Target / mechanism
Prostate-specific membrane antigen (PSMA) PMID 28891033
Clinical application
Targeted alpha therapy of metastatic castration-resistant prostate cancer (dosimetry estimate) PMID 28891033
Theranostic pair
[111In]In-PSMA-617

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [213Bi]Bi-PSMA-617, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68, In-111.
Ask a question